Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M354Revenue $M20.6Net Margin (%)-134.5Z-Score4.2
Enterprise Value $M306EPS $-0.2Operating Margin %-135.8F-Score4
P/E(ttm))0Cash Flow Per Share $-0.0Pre-tax Margin (%)-135.8Higher ROA y-yY
Price/Book7.210-y EBITDA Growth Rate %-12.8Quick Ratio2.5Cash flow > EarningsY
Price/Sales14.85-y EBITDA Growth Rate %-5.4Current Ratio2.9Lower Leverage y-yY
Price/Cash Flow0y-y EBITDA Growth Rate %0ROA % (ttm)-36.6Higher Current Ratio y-yN
Dividend Yield %0Insider Buy (3m)2ROE % (ttm)-48.9Less Shares Outstanding y-yN
Payout Ratio %0Shares Outstanding M132ROI % (ttm)-30.0Gross Margin Increase y-yY

Gurus Latest Trades with ATRS

Number of guru portfolios checked: 85. (List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
ATRSJean-Marie Eveillard 2012-06-30 Sold Out $2.63 - $3.3
($3.04)
$ 2.65-13%Sold Out0
ATRSJean-Marie Eveillard 2010-06-30 Buy $1.48 - $1.95
($1.66)
$ 2.6560%New holding, 20000 sh.20,000
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

ATRS is held by these Gurus:

Ticker Guru Name Portfolio Date* Current Shares % of Shares Outstanding % of Total Assets Managed Change from Last Holdings Holding History
ATRS Jean-Marie Eveillard 2014-12-3120,0000.020
Premium Most recent portfolio changes are included for Premium Members only!


ATRS: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
Fickenscher James ESenior Vice President & CFO 2014-12-11Buy40,000$2.57.6view
HOBBS EAMONN PPresident and CEO 2014-09-10Buy9,000$2.222.27view
ROCHE ROBERT P JRDirector 2014-08-13Buy5,000$1.9637.24view
GUETH ANTONDirector 2014-08-11Buy5,000$234.5view
GARRITY THOMAS JDirector 2014-08-11Buy5,000$1.9835.86view
SAMSON MARVINDirector 2014-08-11Buy25,000$234.5view
JACOB LEONARD SDirector 2014-08-11Buy10,000$1.9835.86view
Wotton Paul KPresident and CEO 2014-01-15Sell22,900$5.1-47.25view
JACOB LEONARD SDirector 2014-01-15Sell11,400$5.05-46.73view
APPLE ROBERT FExecutive Vice President & CFO 2014-01-10Sell10,000$5-46.2view

Press Releases about ATRS :

    Quarterly/Annual Reports about ATRS:

    News about ATRS:

    Articles On GuruFocus.com
    Weekly CFO Sells Highlight: ATRS, DENN, TTWO, JAH, ACET Jun 11 2013 

    More From Other Websites
    Antares' testosterone injection successful in late-stage study Feb 25 2015
    Antares Pharma Announces Positive Topline Pharmakcokinetic Results From the Quickshot Phase 3 Study... Feb 25 2015
    Antares' testosterone injection meets goal in late-stage study Feb 25 2015
    Antares Pharma Announces Positive Top-Line Pharmacokinetic Results from the QuickShot® Phase 3... Feb 25 2015
    Antares Pharma to Present at the Cowen and Company 35th Annual Healthcare Conference Feb 23 2015
    Antares Pharma to Present at the Cowen and Company 35Th Annual Healthcare Conference Feb 23 2015
    Antares Pharma to Present at the 2015 RBC Capital Markets Global Healthcare Conference Feb 18 2015
    Antares Pharma to Present at the 2015 RBC Capital Markets’ Global Healthcare Conference Feb 18 2015
    Antares Pharma Provides Regulatory Update on Sumatriptan Injection USP Jan 26 2015
    ANTARES PHARMA, INC. Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits Jan 26 2015
    Will Patterson Companies' Safety Measures Hold? - Analyst Blog Jan 19 2015
    Antares Pharma Announces Update to Quick Shot Testosterone Program Jan 13 2015
    FDA seeks more safety data on Antares testosterone drug Jan 13 2015
    ANTARES PHARMA, INC. Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits Jan 13 2015
    Antares Pharma Announces Update to QuickShot® Testosterone Program Jan 13 2015
    ANTARES PHARMA, INC. Files SEC form 8-K, Other Events Jan 09 2015
    Antares Pharma to Present at the 33rd Annual JP Morgan Healthcare Conference Jan 08 2015
    Antares Pharma to Present at the 33rd Annual J.P. Morgan Healthcare Conference Jan 08 2015
    Multiple FDA-Cleared Devices Give This Company Extraordinary Upside Dec 03 2014
    Antares Pharma to Present at the 25th Annual Oppenheimer Healthcare Conference Dec 03 2014

    Add Notes, Comments

    If you want to ask a question, or report a bug, please create a support ticket.

    User Comments

    No comment yet
    Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
    GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
    Free 7-day Trial
    FEEDBACK